Dr. Ekman has served as a member of the Ultragenyx Board since March 2016. He has more than 30 years of experience in senior executive, scientific and clinical functions. He is currently an Executive Partner at Sofinnova Ventures, a role which he has had since 2008. Dr. Ekman previously served as Co-Founder and Chief Executive Officer of Cebix Inc, a C-peptide replacement therapy company. Prior to that he served as President of Research and Development at Elan, where he is credited with advancing the company’s pipeline and leading a team that received approval for four U.S. New Drug Applications and three European Marketing Authorization Applications and and received clearance for five Investigational New Drug Applications. Before joining Elan, Dr. Ekman led research and development at Schwarz Pharma AG, and prior to that, he held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer). Dr. Ekman serves as Chairman of the Board of Amarin Corporation plc and Prothena Corporation plc. Dr. Ekman is a board-certified surgeon who has held several clinical and academic positions in the United States and Europe. He earned an M.D. and a Ph.D. in experimental biology from the University of Gothenburg, Sweden.